Pembrolizumab After ASCT for Hodgkin Lymphoma, DLBCL and T-NHL

Clinical trial NCT02362997 · COMPLETED

Trial details

NCT number: NCT02362997
Sponsor: Dana-Farber Cancer Institute
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Hodgkin Lymphoma Diffuse Large B Cell Lymphoma Peripheral T-Cell Lymphoma

Start date: 2015-04-01
Primary completion: 2021-10-26
Enrollment: 82

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.